CLINICAL INVESTIGATION OF A NEW CLASS-III ANTIARRHYTHMIC DRUG NIBENTAN .1. TOLERABILITY STUDY

Results of a tolerance study of a new class III antiarrhythmic drug ni bentan are presented. Effect of an intravenous bolus injection of 0.06 25 - 0.5 mg/kg was investigated in 67 patients with different supraven tricular end ventricular tachycardias. Nibentan produced effects chara cteristic of class III antiarrhythmic drugs: appearance of an addition al U wave simultaneously with lowering of T wave amplitude and prolong ation of Q - T (U), interval by 34%. Nibentan did not affect Intraatri al, atrioventricular and intraventricular conduction at normal heart r ate. Nibentan significantly slowed sinus rhythm rate. The drug caused no pathological effect on arterial blood pressure, myocardial contract ility, biochemical parameters of blood and urine. Nibentan was subject ively well tolerated. Three patients (4.5%) developed pronounced brady cardia. The paper does not contain data on arrhythmogenic effects of n ibentan.